5 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Not yet recruiting 1, Terminated 1, Unknown 1 |
Follow Eptifibatide: new trials by email Literature Review of Eptifibatide trials Research Report on Eptifibatide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis Eptifibatide (Integrilin), Standard Medical Therapy - Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Xinqiao Hospital of Chongqing | 786 | 2026-03-01 | 2026-01-16 |
| Multi-arm Optimization of Stroke Thrombolysis Argatroban, Eptifibatide, Placebo - Acute Ischemic Stroke | Phase 3 | Completed | Washington University School of Medicine | 514 | 2019-10-15 | 2025-02-07 |
| Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH) Eptifibatide Injection - Acute Ischemic Stroke | Phase 3 | Unknown | Ministry of Science and Technology of the People´s Republic of China | 220 | 2019-04-06 | 2019-06-18 |
| Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy Otamixaban, Placebo (for Otamixaban), UFH - Acute Coronary Syndrome | Phase 3 | Completed | Sanofi | 13220 | 2010-04-01 | 2016-05-04 |
| INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial eptifibatide, placebo - Cardiovascular Disease | Phase 3 | Completed | Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS | 91 | 2007-11-01 | 2010-05-28 |
| Eptifibatide and ST Segment Resolution Following Primary PCI eptifibitide - Myocardial Infarction | Phase 3 | Terminated | Medstar Health Research Institute | 22 | 2007-08-01 | 2014-08-11 |
| Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI) Abciximab, Eptifibatide - Infarction, Myocardial | Phase 3 | Completed | GlaxoSmithKline | 429 | 2006-10-01 | 2012-11-27 |
| EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) Eptifibatide (Integrilin), Placebo - Myocardial Ischemia, Acute Coronary Syndrome | Phase 3 | Completed | Organon and Co | 9406 | 2004-11-01 | 2024-05-17 |
Ischemic Stroke (3) · Myocardial Infarction (3) · Acute Coronary Syndrome (2) · Cardiovascular Diseases (2) · ST Elevation Myocardial Infarction (2) · Angina Pectoris (1) · Coronary Artery Disease (1) · Ischemia (1) · Myocardial Ischemia (1)
Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS (1) · GlaxoSmithKline (1) · Medstar Health Research Institute (1) · Ministry of Science and Technology of the People´s Republic of China (1) · Organon and Co (1) · Sanofi (1) · Washington University School of Medicine (1) · Xinqiao Hospital of Chongqing (1)
United States (3) · China (2) · France (2) · Germany (2) · Italy (2) · Argentina (1) · Australia (1) · Austria (1) · Belarus (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Colombia (1)
Daojun Hong, MD (1) · Opeolu Adeoye, MD (1) · Ron Waksman, MD (1) · Zhenqiang Zhao, MD (1) · Zhongming Qiu, MD (1)
PMID 19332455, PMID 20670755, PMID 21300952, PMID 22373905, PMID 22645292, PMID 22995880, PMID 23416014, PMID 23537976, PMID 23995608, PMID 24016495, PMID 24093853, PMID 24562802, PMID 24607027, PMID 26957532, PMID 28052979, PMID 28089149, PMID 29895599, PMID 31976867, PMID 3201508, PMID 33296224, PMID 33297893, PMID 33427887, PMID 33430604, PMID 33518473, PMID 34329730, PMID 34838189, PMID 35105182, PMID 35130717, PMID 35224730, PMID 36711206, PMID 37256980, PMID 39231343, PMID 40123511, PMID 40824660, PMID 41071964
2009 (1), U01NS100699 (1)